Tissue Regenix Group PLC Distribution agreement - OrthoPure(R) XT in Germany (1322H)
November 22 2022 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 1322H
Tissue Regenix Group PLC
22 November 2022
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or 'the Group')
Distribution agreement for OrthoPure (R) XT in Germany
Second European distribution agreement signed in 2022 as part of
the European growth strategy
Tissue Regenix Group (AIM: TRX), the regenerative medical
devices company, announces that it has signed an exclusive
distribution agreement with 2med GmbH ('2med'), a Hamburg - based
service provider for surgical and orthobiological treatments of the
musculoskeletal system, for the distribution of OrthoPure (R) XT in
Germany.
The multiyear distribution agreement currently covers Germany .
However, it also has the potential for extension into additional
territories covered by 2med representatives. 2med is an independent
specialist dealer of surgical and biological therapy procedures for
shoulder, knee, foot and ankle, with a focus on treatments that
support an active and independent lifestyle.
The OrthoPure (R) XT decellularised xenograft ligament utilises
Tissue Regenix's patented dCell(R) technology and is the only
available non-human biologic graft indicated for certain ligament
reconstruction procedures. The CE - marked OrthoPure (R) XT can be
used for revision of anterior cruciate ligament (ACL)
reconstruction procedures and reconstruction of other knee
ligaments, including multi-ligament and primary procedures when the
autograft is not an option.
Thomas Guenther, Commercial Director at 2med, commented : " 2med
are delighted to be representing OrthoPure (R) XT in Germany. The
initial feedback from our knee surgeons is very positive and we are
excited to offer this new, easy to use option for German patients
with damaged ACL and other knee ligaments ."
Daniel Lee, Chief Executive Officer of Tissue Regenix Group,
commented: "Following the success of our partnership with Geistlich
Biomaterials Italia, that we announced in March 2022, we are
pleased to have signed this distribution agreement with 2med for
Germany. 2med's work with doctors and patients, to offer advanced
treatments and minimise rehabilitation times, are aligned with this
innovative product and has made 2med one of the leading specialist
dealers in Germany. We look forward to working with 2med and
continuing to expand the use of OrthoPure (R) XT across
Europe."
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Tel: +44(0)20 7710 7600
Adviser and Broker)
Ben Maddison / Nick Harland / Kate Hanshaw
Walbrook PR Ltd Tel: +44(0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue, leaving an acellular tissue
scaffold, which is not rejected by the patient's body and can then
be used to repair diseased or damaged body structures. Current
applications address many critical clinical needs in sports
medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specialises in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, dental and ophthalmological surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAEFFALEAFAA
(END) Dow Jones Newswires
November 22, 2022 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024